Trial Profile
A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Metformin (Primary)
- Indications Fragile X syndrome
- Focus Therapeutic Use
- 21 Jul 2023 Planned number of patients changed from 60 to 120.
- 21 Jul 2023 Planned End Date changed from 30 Apr 2022 to 31 Dec 2023.
- 21 Jul 2023 Planned primary completion date changed from 1 Dec 2021 to 31 Dec 2023.